A panel of serum glycoprotein biomarkers can discriminate between patients with Barrett’s oesophagus who do not require further intervention and those who have progressed to oesophageal adenocarcinoma. The research, led by a team at QIMR Berghofer Medical Research Institute, holds the promise of a screening test to detect oesophageal adenocarcinoma at the earliest opportunity. It ...
Already a member?
Enter your email to keep reading.